Stocks in Play: Satellos Bioscience Inc.
Thursday, May 22, 2025
9:52 AM EST - Satellos Bioscience Inc. : Announced promising Phase 1b data, in an open-label study treating five adult male DMD patients, ages 20 – 27, demonstrating early signs that SAT-3247 may have the potential to affect grip strength, which could represent a clinically meaningful measure for patients with DMD. Satellos Bioscience Inc. (T.MSCL) shares were up $0.02 at 0.67.Stocks in Play: Satellos Bioscience Inc. , Thu, 22 May 2025 09:57:06 EST
